Pfizer and BioNTech's COVID Vaccine: A Game Changer in Trials
Written on
Chapter 1: Promising Developments in Vaccine Trials
In a week marked by a surge in COVID-19 cases across the United States, a beacon of hope emerges from an unexpected source. The collaboration between Pfizer, an American pharmaceutical giant, and its German partner, BioNTech, has yielded promising results from their COVID vaccine trials. Initial findings indicate a remarkable 90% efficacy rate among the first 94 participants. Their optimistic results suggest they may soon seek FDA approval to distribute the vaccine as early as the end of November.
To appreciate what sets their vaccine apart, it’s essential to first grasp the fundamental concept of a vaccine.
What is a Vaccine?
Vaccines are designed to equip the immune system to combat illnesses for which it may not have inherent defenses. They enhance our immune response by mimicking the presence of pathogens, thus training the body to recognize and neutralize them. When harmful bacteria invade our system, various signals are triggered, prompting white blood cells to coordinate an attack, with some producing antibodies that specifically target the invaders.
Antibodies function like unique keys that unlock defenses against particular pathogens and remain in our system for future encounters. Vaccines induce the production of these antibodies tailored to specific bacteria or viruses.
What Type of Vaccine is Being Developed?
The vaccine created by Pfizer and BioNTech employs a cutting-edge approach known as Messenger RNA (mRNA) technology. To fully understand this, we must first differentiate between RNA and DNA. If we liken RNA and DNA to basketball legends, DNA would be Michael Jordan, the star with all the critical information stored within the cell’s nucleus, while RNA plays a supportive yet crucial role, akin to John Stockton.
RNA, or ribonucleic acid, is a copy of DNA that can move freely within the cell, delivering vital instructions from DNA to the cytoplasm, where proteins are synthesized.
What is a Ribosome?
Ribosomes are essential cellular structures that function as protein factories, located in the cytoplasm. When RNA delivers its message, ribosomes interpret the code and synthesize specific proteins, in this case, proteins that will provide immunity against COVID-19.
What is Messenger RNA?
Messenger RNA (mRNA) is the specific type of RNA responsible for transporting genetic instructions from the DNA to the ribosomes. Upon reaching the ribosome, the mRNA is read, leading to the production of a protein designed to elicit an immune response against the coronavirus. This vaccine strategically isolates the genes responsible for the virus's spike proteins, prompting the body to build defenses against these proteins upon vaccination, unlike traditional vaccines that use the entire virus.
What Comes Next?
After the initial trials, the FDA mandates a two-month observation period to monitor any side effects. Pfizer anticipates completing this assessment by the third week of November. However, the duration of immunity conferred by the vaccine remains uncertain, as the study is still in its early phases.
The first video titled "Covid-19: Researcher blows the whistle on data integrity issues in Pfizer's vaccine trial" discusses concerns surrounding the integrity of data presented in clinical trials, shedding light on critical issues that may affect the vaccine’s rollout.
The second video, "The COVID-19 mRNA vaccines given to the public weren't those studied in the clinical trials," explores the discrepancies between the vaccines administered to the public and those that were part of the clinical trials, raising important questions about vaccine safety and efficacy.